News | Biogen

October 17, 2021

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observed The

October 14, 2021

Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting

October 13, 2021

New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

List View Grid View

May 1, 2019

Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases

Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA ® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood development Late-breaking data expand on safety and exploratory efficacy results of a study investigating tofersen

April 30, 2019

Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy

Patients, aged five up to 19, treated with SPINRAZA over three years demonstrated clinically significant improvements in motor function and stabilization of disease activity One individual gained the ability to walk independently – an achievement that has not been previously observed in untreated

April 29, 2019

Biogen Announces Three New Nominees for Election to Board of Directors

Nominees Bring Decades of Management and Global Operating Experience, Including at Leading Healthcare Companies CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced the nomination of John R. Chiminski, William A. Hawkins and Jesus B.

April 12, 2019

Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference

Adults with later-onset spinal muscular atrophy (SMA) who are not being treated show increased rates of hospital admissions, clinical interventions and mortality, indicating an unmet medical need Infants with pre-symptomatic SMA treated with SPINRAZA® (nusinersen) achieve motor milestones that are

March 27, 2019

Biogen to Present at the Stifel First Annual CNS Day

Cambridge, MA, - - Biogen Inc. (Nasdaq:BIIB) announced today that Michael Ehlers, M.D., Ph.D., executive vice president, research and development at Biogen, will present at the Stifel First Annual CNS Day. The webcast will be live on Monday, April 1, at 12:00 p.m. ET.

March 21, 2019

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease

Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the

March 13, 2019

Biogen to Report First Quarter 2019 Financial Results April 24, 2019

Cambridge, MA, — Biogen Inc. (Nasdaq:BIIB) today announced it will report first quarter 2019 financial results Wednesday, April 24, 2019, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET.

March 12, 2019

Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm

Approximately 800 employees at Hillerød site expected to continue employment under Fujifilm ownership Biogen will enter into manufacturing services agreements with Fujifilm to supply TYSABRI ® and third-party products Biogen expects new manufacturing facility in Solothurn, Switzerland to be

March 5, 2019

Biogen to Present at the Cowen 39th Annual Health Care Conference

Cambridge, MA, - - Biogen Inc. (Nasdaq:BIIB) announced today that it will present at the Cowen 39th Annual Health Care Conference. The webcast will be live on Monday, March 11, at 11:20 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at http://investors.biogen.com/ .

March 4, 2019

Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology

Biogen to acquire Nightstar Therapeutics for $25.50 per share Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering from rare inherited retinal diseases that would otherwise lead to blindness Nightstar has two potentially first-in-class mid-